Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 6th. Analysts expect Ironwood Pharmaceuticals to post earnings of ($0.19) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Monday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The firm had revenue of $81.10 million for the quarter, compared to analysts’ expectations of $82.61 million. Ironwood Pharmaceuticals’s revenue was up 24.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.28) EPS. On average, analysts expect Ironwood Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Ironwood Pharmaceuticals stock traded down $1.84 on Tuesday, hitting $14.25. 1,070,522 shares of the company traded hands, compared to its average volume of 1,109,460. The stock has a market cap of $2.52 billion, a P/E ratio of -15.32 and a beta of 0.79. Ironwood Pharmaceuticals has a 52 week low of $12.89 and a 52 week high of $21.20.
Several equities research analysts recently weighed in on the stock. Cowen restated a “market perform” rating on shares of Ironwood Pharmaceuticals in a research report on Wednesday, July 18th. HC Wainwright assumed coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, July 23rd. They issued a “sell” rating and a $12.50 price target on the stock. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 6th. ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. Finally, Wells Fargo & Co set a $23.00 price target on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $19.00.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
Recommended Story: Google Finance
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.